• PDF: Delivered by email usually within 24 to 48 UK business hours.

Dyslipidemia Therapeutics

Dyslipidemia Therapeutics

This report analyzes the worldwide markets for Dyslipidemia Therapeutics in US$ Million by the following segments - Statins, and Non-Statins. The report provides separate comprehensive analytics for US, Japan, Europe, and Rest of World. Annual estimates and forecasts are provided for each region for the period 2006 through 2015. The report profiles 41 companies including many key and niche players worldwide such as Abbott Laboratories, AstraZeneca, PLC, GlaxoSmithKline, Inc., Merck & Co., Inc., Mylan, Inc., Novartis AG, Pfizer, Inc., and Teva Pharmaceutical Industries Ltd. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

  • I.Introduction, Methodology & Product Definitions
    • Study Reliability and Reporting Limitations
    • Disclaimers
    • Data interpretation & Reporting Level
    • Quantitative Techniques & Analytics
    • Product Definitions and Scope of Study
    • Statins
    • Non-Statins
  • II. Executive Summary
    • 1.Global Market Overview
    • Outlook
    • Global Market Analysis
    • Plummeting Growth for Statins
    • Non-Statin Drug Segment to Drive Future Growth
    • Major Drugs Face Patent Expiry
    • Major Dyslipidemia Drugs & Patent Expiry
    • Key Challenges Faced by Dyslipidemia Market
    • Patents Expiry
    • Generic Penetration
    • Table 1: increasing Penetration of Generics in the US and European Dyslipidemia therapeutics Market by Volume (2005-2009) (Includes Corresponding Graph/Chart)
    • Strict Fda Regulations
    • Pipeline Drugs: Focused On Unmet Needs
    • List of Select Pipeline Drugs for Treatment of Dyslipidemia (2009)
    • Novel Combination Products and Future therapies to Change Landscape
    • Fixed-Dose Combination therapies
    • Simcor - the foremost Fixed-Dose Combination
    • Certriad
    • Combination therapy – Treatment for Diabetic Dyslipidemia
    • Market Competition and Brand Dynamics
    • Lipitor – top Selling Statin
    • Table 2: Lipitor Sales Worldwide (2004-2008) (In Us$ Billion) (Includes Corresponding Graph/Chart)
    • Crestor – the Rising Statin
    • Table 3: Crestor Sales Worldwide (2004-2008) (In Us$ Billion) (Includes Corresponding Graph/Chart)
    • Vytorin (Ezetimibe/Simvastatin)
    • Lovaza – the Leading Non-Statin
    • Trilipix –the foremost Combination therapy Drug
    • Table 4: Leading Non-Statin Brands in the US and Europe (2009): Percentage Breakdown of Value Sales for Tricor, Niaspan, Lovaza, Antara, Triplix and Others (Includes Corresponding Graph/Chart)
    • 2.Dyslipidemia – An insight
    • Introduction to Dyslipidemia
    • Classification
    • Causes
    • Hereditary Dyslipidemia
    • Types
    • Familial Combined Hyperlipidemia
    • Familial Hypertriglyceridemia
    • Familial Dysbetalipoproteinemia
    • Hypoalphalipoproteinemia
    • Symptoms of Dyslipidemia
    • Co-Morbid Disorders and Risk Factors
    • Diagnosis
    • Treatment Strategies
    • Drug therapy
    • 3.Treatment of Dyslipidemia
    • Classes of Antidyslipidemic Drugs
    • Statins
    • Types of Statins
    • Various Types of Statins Along with their Brand Names and Availability in Market as Prescription Generic Drugs
    • Growth Drivers for Statins
    • Impediments to Growth
    • Non-Statins
    • Types of Non-Statins
    • Fibric Acid Derivatives
    • Bile Acid Sequestrants
    • Cholesterol Absorption inhibitors
    • Potential Growth Drivers for Non-Statins
    • Market Opportunities
    • Non-Statin Products in Pipeline
    • Select Non -Statin Drugs in Pipeline (2009)
    • Lipoprotein Synthesis inhibitor
    • Fat Supplements
    • 4.Product Approvals and Clinical Trials
    • Kowa Pharmaceuticals America Receives Fda Approval for Livalo
    • Aegerion Pharmaceuticals Releases Final Data for Lomitapide (Aegr-733) Phase Ii Trials
    • Dr Reddy's Laboratories Obtains Approval for Two Drugs
    • Arena Pharmaceuticals Commences Phase Ii Clinical Trial for Niacin Receptor Agonist
    • Abbott Laboratories and Solvay Pharmaceuticals Receives Fda Approval for Trilipix
    • Astrazeneca and Abbott Submit Nda for Certriad™
    • Amarin Secures Fda Approval for Amr101 Phase Iii Trials
    • Abbott's Receives Approval for Using Trilipix® as a Combination therapy
    • Takeda Commences Phase Iii Trial for Atl-962
    • Aaipharma Licenses Procr Oral Drug Delivery Technology to Cortria
    • Essentialis Finishes Patient Enrolment Process
    • Metabolex Releases Results From Phase Ii Clinical Trial for Mbx-8025
    • Karo Bio Releases Phase Ii Study Results for Eprotirome
    • Merck Sharp & Dohme Receives Approval for Tredaptive
    • Merck Obtains Patent Approval for Two Drugs
    • Resverlogix Completes Phase 1a Trials for Rvx-208
    • Abbott Obtains Approval From Fda for Simcor
    • Surface Logix Releases Results of Phase 2a Clinical Trial for Slx-4090
    • Merck's Cholesterol Pill to Receive Fda Approval in 2013
    • Schering-Plough Obtains Approval for Marketing Zetia®
    • 5.Recent industry Activity
    • Abbott and Solvay Group Enter into Definitive Agreement
    • Daiichi Sankyo Establishes New Subsidiary
    • Astrazeneca introduces Crestor
    • Kowa Takes Over Proethic Pharmaceuticals
    • Ore Pharmaceuticals Acquires Exclusive Rights From Roche to Develop Romazarit
    • Astrazeneca Enters into Agreement with Abbott
    • Pfizer Sells Esperion therapeutics
    • Merck Establishes New Biotechnology Division
    • Glaxosmithkline Acquires Reliant Pharmaceuticals
    • 6.Focus On Select Global Players
    • Abbott Laboratories (Us)
    • Astrazeneca, Plc (Uk)
    • Glaxosmithkline, inc. (Us)
    • Merck & Co., inc. (Us)
    • Mylan, inc. (Us)
    • Novartis Ag (Switzerland)
    • Pfizer, inc. (Us)
    • Teva Pharmaceutical industries Ltd. (Israel)
    • 7.Global Market Perspective
    • Table 5: World Recent Past, Current & Future Analysis for Dyslipidemia therapeutics by Geographic Region/Country – Us, Japan, Europe, and Rest of World Markets independently Analyzed with Annual Sales Figures in Us$ Million for Years 2006 Through 2015 (Includes Corresponding Graph/Chart)
    • Table 6: World 10-Year Perspective for Dyslipidemia therapeutics by Geographic Region/Country – Percentage Breakdown of Dollar Sales for Us, Japan, Europe, and Rest of World Markets for Years 2006, 2009 & 2015 (Includes Corresponding Graph/Chart)
    • Table 7: World Recent Past, Current & Future Analysis for Statins by Geographic Region/Country – Us, Japan, Europe, and Rest of World Markets independently Analyzed with Annual Sales Figures in Us$ Million for Years 2006 Through 2015 (Includes Corresponding Graph/Chart)
    • Table 8: World 10-Year Perspective for Statins by Geographic Region/ Country – Percentage Breakdown of Dollar Sales for Us, Japan, Europe, and Rest of World Markets for Years 2006, 2009 & 2015 (Includes Corresponding Graph/Chart)
    • Table 9: World Recent Past, Current & Future Analysis for Non-Statins by Geographic Region/Country – Us, Japan, Europe, and Rest of World Markets independently Analyzed with Annual Sales Figures in Us$ Million for Years 2006 Through 2015 (Includes Corresponding Graph/Chart)
    • Table 10: World 10-Year Perspective for Non-Statins by Geographic Region/ Country – Percentage Breakdown of Dollar Sales for Us, Japan, Europe, and Rest of World Markets for Years 2006, 2009 & 2015 (Includes Corresponding Graph/Chart)
  • III. Market
    • 1.The United States
    • A. Market Analysis
    • Outlook
    • Demographics
    • Dyslipidemia in Elderly Population
    • Market Share Statistics
    • Table 11: the US Market for Antidyslipidemic Drugs (2007): Percentage Share Breakdown of Leading Brands by Prescription - Lipitor, Vytorin, Zetia, Crestor, Tricor, Niaspan and, Others (Includes Corresponding Graph/Chart)
    • Product Approvals and Clinical Trials
    • Strategic Corporate Developments
    • Key Players
    • B. Market Analytics
    • Table 12: US Recent Past, Current & Future Analysis for Dyslipidemia therapeutics by Product Segment – Statins and Non-Statins Markets independently Analyzed with Annual Sales Figures in Us$ Million for Years 2006 Through 2015 (Includes Corresponding Graph/Chart)
    • Table 13: US 10-Year Perspective for Dyslipidemia therapeutics by Product Segment –– Percentage Breakdown of Dollar Sales for Statins and Non-Statins Markets for 2006, 2009, and 2015
    • 2.Japan
    • A. Market Analysis
    • Strategic Corporate Developments
    • B. Market Analytics
    • Table 14: Japanese Recent Past, Current & Future Analysis for Dyslipidemia therapeutics by Product Segment – Statins and Non-Statins Markets independently Analyzed with Annual Sales Figures in Us$ Million for Years 2006 Through 2015 (Includes Corresponding Graph/Chart)
    • Table 15: Japanese 10-Year Perspective for Dyslipidemia therapeutics by Product Segment – Percentage Breakdown of Dollar Sales for Statins and Non-Statins Markets for 2006, 2009, and 2015
    • 3.Europe
    • A. Market Analysis
    • Strategic Corporate Developments
    • B. Market Analytics
    • Table 16: European Recent Past, Current & Future Analysis for Dyslipidemia therapeutics by Geographic Region – France, Germany, Italy, Uk, Spain, & Rest of Europe Markets independently Analyzed with Annual Sales Figures in Us$ Million for Years 2006 Through 2015 (Includes Corresponding Graph/Chart)
    • Table 17: European 10-Year Perspective for Dyslipidemia therapeutics by Geographic Region –percentage Breakdown of Dollar Sales for France, Germany, Italy, Uk, Spain, & Rest of Europe Markets for 2006, 2009, and 2015 (Includes Corresponding Graph/Chart)
    • Table 18: European Recent Past, Current & Future Analysis for Dyslipidemia therapeutics by Product Segment – Statins and Non-Statins Markets independently Analyzed with Annual Sales Figures in Us$ Million for Years 2006 Through 2015 (Includes Corresponding Graph/Chart)
    • Table 19: European 10-Year Perspective for Dyslipidemia therapeutics by Product Segment – Percentage Breakdown of Dollar Sales for Statins and Non-Statins Markets for 2006, 2009, and 2015
    • 3a.France
    • Market Analysis
    • Table 20: French Recent Past, Current & Future Analysis for Dyslipidemia therapeutics by Product Segment – Statins and Non-Statins Markets independently Analyzed with Annual Sales Figures in Us$ Million for Years 2006 Through 2015 (Includes Corresponding Graph/Chart)
    • Table 21: French 10-Year Perspective for Dyslipidemia therapeutics by Product Segment – Percentage Breakdown of Dollar Sales for Statins and Non-Statins Markets for 2006, 2009, and 2015
    • 3b.Germany
    • Market Analysis
    • Table 22: German Recent Past, Current & Future Analysis for Dyslipidemia therapeutics by Product Segment – Statins and Non-Statins Markets independently Analyzed with Annual Sales Figures in Us$ Million for Years 2006 Through 2015 (Includes Corresponding Graph/Chart)
    • Table 23: German 10-Year Perspective for Dyslipidemia therapeutics by Product Segment – Percentage Breakdown of Dollar Sales for Statins and Non-Statins Markets for 2006, 2009, and 2015
    • 3c.Italy
    • Market Analysis
    • Table 24: Italian Recent Past, Current & Future Analysis for Dyslipidemia therapeutics by Product Segment – Statins and Non-Statins Markets independently Analyzed with Annual Sales Figures in Us$ Million for Years 2006 Through 2015 (Includes Corresponding Graph/Chart)
    • Table 25: Italian 10-Year Perspective for Dyslipidemia therapeutics by Product Segment – Percentage Breakdown of Dollar Sales for Statins and Non-Statins Markets for 2006, 2009, and 2015
    • 3d.The United Kingdom
    • Market Analysis
    • Table 26: Uk Recent Past, Current & Future Analysis for Dyslipidemia therapeutics by Product Segment – Statins and Non-Statins Markets independently Analyzed with Annual Sales Figures in Us$ Million for Years 2006 Through 2015 (Includes Corresponding Graph/Chart)
    • Table 27: Uk 10-Year Perspective for Dyslipidemia therapeutics by Product Segment – Percentage Breakdown of Dollar Sales for Statins and Non-Statins Markets for 2006, 2009, and 2015
    • 3e.Spain
    • Market Analysis
    • Table 28: Spanish Recent Past, Current & Future Analysis for Dyslipidemia therapeutics by Product Segment – Statins and Non-Statins Markets independently Analyzed with Annual Sales Figures in Us$ Million for Years 2006 Through 2015 (Includes Corresponding Graph/Chart)
    • Table 29: Spanish 10-Year Perspective for Dyslipidemia therapeutics by Product Segment – Percentage Breakdown of Dollar Sales for Statins and Non-Statins Markets for 2006, 2009, and 2015
    • 3f.Rest of Europe
    • Market Analysis
    • Table 30: Rest of Europe Recent Past, Current & Future Analysis for Dyslipidemia therapeutics by Product Segment – Statins and Non-Statins Markets independently Analyzed with Annual Sales Figures in Us$ Million for Years 2006 Through 2015 (Includes Corresponding Graph/Chart)
    • Table 31: Rest of Europe 10-Year Perspective for Dyslipidemia therapeutics by Product Segment – Percentage Breakdown of Dollar Sales for Statins and Non-Statins Markets for 2006, 2009, and 2015
    • 4.Rest of World
    • A. Market Analysis
    • China
    • Outlook
    • Key Players
    • Strategic Corporate Developments
    • B. Market Analytics
    • Table 32: Rest of World Recent Past, Current & Future Analysis for Dyslipidemia therapeutics by Product Segment – Statins and Non-Statins Markets independently Analyzed with Annual Sales Figures in Us$ Million for Years 2006 Through 2015 (Includes Corresponding Graph/Chart)
    • Table 33: Rest of World 10-Year Perspective for Dyslipidemia therapeutics by Product Segment – Percentage Breakdown of Dollar Sales for Statins and Non-Statins Markets for 2006, 2009, and 2015
    • IV. Competitive Landscape
    • Total Companies Profiled: 41 (Including Divisions/Subsidiaries - 43)
    • Region/Countryplayers
    • The United States23
    • Canada
    • Japan
    • Europe
    • France
    • The United Kingdom
    • Italy
    • Rest of Europe
    • Asia-Pacific (Excluding Japan)
    • Middle-East
+44 20 8816 8548

Ask a question about Dyslipidemia Therapeutics

Enter the characters you see in the picture below
Captcha